TCRT Alaunos Therapeutics, Inc.: institutional ownership and insider trading
32 funds reported holding $302K of Alaunos Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net sold $80.3K, with 6 new positions and 4 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $3.00K and net income of −$4.01M.
TCRT revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$952K, EPS -0.41
- Quarter ended Mar 31, 2026: revenue $0, net income −$1.01M, EPS -0.59
- Quarter ended Dec 31, 2025: revenue $3.00K, net income −$893K, EPS -0.35
- Quarter ended Sep 30, 2025: revenue $0, net income −$1.16M, EPS -0.55
Famous investors holding TCRT
- Ken Griffin (Citadel Advisors): $26.8K, 0.0% of the portfolio
Largest institutional holders of TCRT
- VANGUARD GROUP INC — $97.1K
- BlackRock, Inc. (BLK) — $48.3K
- GEODE CAPITAL MANAGEMENT, LLC — $43.8K
- VANGUARD FIDUCIARY TRUST CO — $35.0K
- VANGUARD CAPITAL MANAGEMENT LLC — $31.8K
- CITADEL ADVISORS LLC — $26.8K
- OSAIC HOLDINGS, INC. — $3.91K
- Tower Research Capital LLC (TRC) — $3.66K
- Arax Advisory Partners — $2.75K
- UBS Group AG (UBS) — $2.24K
Recent TCRT insider trades
- Dec 31, 2024: Vieser Jaime sold 3,000 shares ($6.02K)
5%+ owners
- Fairmount Funds Management LLC: 20.0% (Schedule 13D, filed Oct 15, 2026)
- Postma Robert W: 10.0% (Schedule 13D/A, filed Oct 15, 2026)
Who owns the most TCRT stock?
The largest institutional holders of Alaunos Therapeutics, Inc. in the latest 13F filings are VANGUARD GROUP INC ($97.1K), BlackRock, Inc. (BLK) ($48.3K), GEODE CAPITAL MANAGEMENT, LLC ($43.8K).
Are insiders buying or selling TCRT?
No open-market insider buys or sells of Alaunos Therapeutics, Inc. were reported in the last 12 months.
Which famous investors own TCRT?
Ken Griffin.
What was TCRT's revenue last quarter?
Alaunos Therapeutics, Inc. reported revenue of $0 for the quarter ended June 30, 2026, with net income of −$952K.